trending Market Intelligence /marketintelligence/en/news-insights/trending/cZ-jnNkRwzT-94j8O_W6rg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Horizon Pharma closes $326.8M ordinary share offering to repay debt

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Horizon Pharma closes $326.8M ordinary share offering to repay debt

Horizon Pharma PLC closed a public offering of 14,081,632 ordinary shares priced at $24.50 each.

Shares sold include the additional 1,836,734 stocks the offering's underwriters could have bought as part of their overallotment option.

Net proceeds from the offering are about $326.8 million. The company previously said it plans to use net proceeds, along with cash on hand, to repay about $550 million of its outstanding debt.

The debt includes a portion of the loans under Horizon Pharma's credit agreement and a portion of an amount of its 6.625% senior notes due 2023.

Citigroup, Morgan Stanley, Goldman Sachs & Co. LLC and Cowen acted as joint book-running managers for the offer.

Dublin-based Horizon Pharma develops medicines that address rare and rheumatic diseases.